ClinicalTrials.gg
CompletedNCT02255435Updated Sep 3, 2026Results posted

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

A Phase 2 interventional study of Omaveloxolone Capsules, 2.5 mg and Omaveloxolone Capsules, 5 mg in Friedreich Ataxia, sponsored by Biogen. Completed at 11 sites in 5 countries. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
2nd of 49
172 · median 32
Started
2015
with 7 others
Phase 2
14 of 71
3 open now
Registered
18th of 71
by date
Lead sponsor
5 of 71
Biogen

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 2nd largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2015, is one of 14 in phase 2, and was the 18th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

In this study, researchers are learning more about RTA 408, also known as omaveloxolone, BIIB141, or SKYCLARYS®. The main goal of this study is to learn more about the safety of RTA 408 and how it affects physical effort, movement, coordination, and how participants feel in daily life.

The main questions researchers want to answer in this study are:

  • How much physical effort can a participant produce during a cycling test after 12 weeks of treatment?
  • How do scores on the modified Friedreich's Ataxia Rating Scale (mFARS) change after 48 weeks?

Researchers will use the modified Friedreich's Ataxia Rating Scale (mFARS) to measure how FA affects the nervous system. The mFARS looks at movement ability, balance, coordination, speech, and how well the arms and legs work.

They will also use a cycling test to measure physical effort, along with questionnaires to learn how participants feel and function in daily life.

Safety will also be tested using physical exams, vital sign checks, echocardiograms (ECHO), electrocardiograms (ECG), and blood and urine tests.

The study will be done in 2 main parts, followed by an optional Extension period:

  • In Part 1, participants will be randomly assigned to take different doses of RTA 408 or a placebo by mouth once a day for 12 weeks. A placebo looks like the study drug but contains no real medicine.
  • Researchers will compare these doses to decide which one to use in Part 2.
  • In Part 2, a different group of participants will take either the chosen dose of RTA 408 (150 mg) or placebo once a day for 48 weeks.
  • Participants who complete Part 1 or Part 2 may be able to join an Extension period, where everyone receives RTA 408.
  • In the Extension period, participants will continue to receive RTA 408 until the drug becomes commercially available or until they leave the study
  • Participants in Part 1 will have up to 9 study visits and 2 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 20 weeks.
  • Participants in Part 2 will have up to 10 study visits and 3 phone calls. If they do not move onto the Extension period, they will stay in the study for up to 61 weeks.
  • Participants in the Extension period will have 2 visits in the first month, followed by visits every 6 months.
Read the detailed description

Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress.

A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which play a major role in disease progression. Studies have demonstrated that nuclear factor erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in participants with Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and induce antioxidant target genes is hypothesized to be therapeutic in participants with Friedreich's ataxia.

This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone (RTA 408) in the treatment of participants with Friedreich's ataxia.

Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in participants with Friedreich's ataxia.

Part 2: The second part of this study is a randomized, placebo-controlled, double-blind, parallel-group study to evaluate the safety and efficacy of omaveloxolone (RTA 408) 150 mg in participants with Friedreich's ataxia. Participants enrolled in Part 2 will be randomized 1:1 to receive omaveloxolone (RTA 408) 150 mg or placebo.

Extension: The extension will assess long-term safety and tolerability of omaveloxolone (RTA 408) in qualified participants with Friedreich's ataxia following completion of Part 1 or Part 2. Participants will not be unblinded to study treatment in Part 1 or Part 2 upon entering the extension study. Participants will receive open-label omaveloxolone (RTA 408) at 150 mg once daily.

03

Conditions studied

  • Friedreich Ataxia

Keywords

  • RTA 408
  • RTA 408 Capsules
  • Oxidative Stress
  • Mitochondrial dysfunction
  • omaveloxolone
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have genetically confirmed Friedreich's ataxia
  2. Have a modified FARS score ≥20 and ≤80
  3. Be male or female and ≥16 years of age and ≤40 years of age
  4. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period
  5. Have the ability to complete maximal exercise testing
  6. Be able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  1. Have uncontrolled diabetes ( >11.0%)
  2. Have B-type natriuretic peptide value >200 pg/mL
  3. Have a history of left-sided heart disease and/or clinically significant cardiac disease
  4. Have known active fungal, bacterial, and/or viral infection, including or hepatitis virus (B or C)
  5. Have known or suspected active drug or alcohol abuse
  6. Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the of , or alanine aminotransferase
  7. Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment
  8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:

    1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)
    2. Moderate or strong inhibitors or inducers of cytochrome P450 3A4 (e.g., carbamazepine, phenytoin, ciprofloxacin, grapefruit juice)
    3. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)
  9. Have participated in any other interventional clinical study within 30 days prior to Study Day 1
  10. Have a cognitive impairment that may preclude ability to comply with study procedures
  11. Prior participation in a trial with omaveloxolone (RTA 408)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Part 1: Omaveloxolone 2.5 and 5 mg

    Participants received omaveloxolone 2.5 mg, oral capsule, QD for 2 weeks, followed by 5 mg Omaveloxolone, oral capsule, QD for 10 weeks.

    Drug: Omaveloxolone Capsules, 2.5 mg · Drug: Omaveloxolone Capsules, 5 mg

  • Experimental
    Part 1: Omaveloxolone 10 mg

    Participants received omaveloxolone 10 mg, oral capsule, QD for 12 weeks.

    Drug: Omaveloxolone Capsules, 10 mg

  • Experimental
    Part 1: Omaveloxolone 20 mg

    Participants received omaveloxolone 20 mg, oral capsule, QD for 12 weeks.

    Drug: Omaveloxolone Capsules, 20 mg

  • Experimental
    Part 1: Omaveloxolone 40 mg

    Participants received omaveloxolone 40 mg, oral capsule, QD for 12 weeks.

    Drug: Omaveloxolone Capsules, 40 mg

  • Experimental
    Part 1: Omaveloxolone 80 mg

    Participants received omaveloxolone 80 mg, oral capsule, QD for 12 weeks.

    Drug: Omaveloxolone Capsules, 80 mg

  • Experimental
    Part 1: Omaveloxolone 160 mg

    Participants received omaveloxolone 160 mg, oral capsule, QD for 12 weeks.

    Drug: Omaveloxolone Capsules, 160 mg

  • Experimental
    Part 1: Omaveloxolone 300 mg

    Participants received omaveloxolone 300 mg, oral capsule, QD for 12 weeks.

    Drug: Omaveloxolone Capsules, 300 mg

  • Placebo comparator
    Part 1: Placebo

    Participants received placebo, oral capsule, QD for 12 weeks.

    Drug: Placebo

  • Experimental
    Part 2: Omaveloxolone 150 mg

    Participants received omaveloxolone 150 mg, oral capsule, QD for 48 weeks.

    Drug: Omaveloxolone Capsules, 150 mg

  • Placebo comparator
    Part 2: Placebo

    Participants received placebo, oral capsule, QD for 48 weeks.

    Drug: Placebo

  • Experimental
    OLE: Placebo/ Omaveloxolone

    All eligible participants who had received either omaveloxone or placebo in Part 1 and eligible participants who received placebo in Part 2 received omaveloxone, 150 mg, oral capsule, QD, until the drug was available through commercial channels or alternate post-trial access mechanisms, or until participant withdrawal, whichever was sooner (up to approximately 370 weeks).

    Drug: Omaveloxolone Capsules, 150 mg

  • Experimental
    OLE: Omaveloxolone/ Omaveloxolone

    All eligible participants who had received omaveloxone in Part 2 continued to receive omaveloxolone, 150 mg, oral capsule, QD until the drug was available through commercial channels or alternate post-trial access mechanisms, or until participant withdrawal, whichever was sooner (up to approximately 370 weeks).

    Drug: Omaveloxolone Capsules, 150 mg

Interventions

  • DrugOmaveloxolone Capsules, 2.5 mg

    Also known as: RTA 408 Capsules 2.5 mg

  • DrugOmaveloxolone Capsules, 5 mg

    Also known as: RTA 408 capsules, 5 mg

  • DrugOmaveloxolone Capsules, 10 mg

    Also known as: RTA 408 capsules, 10 mg

  • DrugPlacebo
  • DrugOmaveloxolone Capsules, 20 mg

    Also known as: RTA 408 capsules, 20 mg

  • DrugOmaveloxolone Capsules, 40 mg

    Also known as: RTA 408 capsules, 40 mg

  • DrugOmaveloxolone Capsules, 80 mg

    Also known as: RTA 408 capsules, 80 mg

  • DrugOmaveloxolone Capsules, 160 mg

    Also known as: RTA 408 capsules, 160 mg

  • DrugOmaveloxolone Capsules, 300 mg

    Also known as: RTA 408 capsules, 300 mg

  • DrugOmaveloxolone Capsules, 150 mg

    Also known as: RTA 408 capsules, 150 mg

06

What researchers measure

Primary outcomes

  1. Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12

    Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.

    Time frame: Baseline, Week 12

  2. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug up to end of Part 1 of the study (up to Week 16)

  3. Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48

    The Friedreich Ataxia Rating Scale (FARS) is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.

    Time frame: Baseline, Week 48

  4. Part 2: Number of Participants With TEAEs and TESAEs

    An AE was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug up to end of Part 2 of the study (up to Week 52)

Secondary outcomes

  1. Part 1: Change From Baseline in the mFARS at Week 12

    The FARS is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.

    Time frame: Baseline, Week 12

  2. Part 2: Number of Participants With Patient Global Impression of Change (PGI-C)

    The PGI-C is a 7-point scale that requires participants to assess how much their illness has improved or worsened relative to their baseline state at the beginning of the trial. Participants self-rated their perceived change by completing the following statement: "Since I began trial treatment, my overall status is:" 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse and 7=Very much worse. Lower score indicates better improvement. The categories with at least one participant having a PGI-C score are reported.

    Time frame: Week 48

  3. Part 2: Number of Participants With Clinical Global Impression of Change (CGI-C)

    The CGIC scale is a 7 point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of an intervention. The CGIC was assessed by completing the following statement "Compared to the participant's condition at the start of the trial, this participant's overall status is", where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Lower score indicates better improvement. The categories with at least one participant having a CGIC score are reported.

    Time frame: Week 48

  4. Part 2: Change From Baseline in Performance on a 9-Hole Peg Test (9-HPT) at Week 48

    The 9-HPT is a brief, standardized, quantitative test of upper extremity (arm and hand) function. Both the dominant and nondominant hands were tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand). The participant picks up pegs 1 at a time (9 in total), using 1 hand only, and places them into holes on the board as quickly as possible, in any order until all holes are filled. Then, without pausing, the participant removes the pegs 1 at a time and returns them as quickly as possible. The times recorded for the two trials for each hand are averaged, and the reciprocal average value for each hand was used in analyses. Longer test times reflect more impairment on the participant's upper extremity function, thus a negative change from baseline suggests an improvement.

    Time frame: Baseline, Week 48

  5. Part 2: Change From Baseline in Performance on a 25-Foot Timed Walk Test (T25-FWT) at Week 48

    The T25-FWT is a quantitative mobility and leg function performance test based on time (in seconds) to complete a 25-foot walk. Participants were instructed to attempt two T25-FWT trials at each visit. Both walk times were averaged, and the reciprocal average value was used in analyses. Longer test times reflect more impairment on the participant's ability to walk, thus a negative change from baseline suggests an improvement.

    Time frame: Baseline, Week 48

  6. Part 2: Total Number of Falls

    A fall was defined as "the participant unintentionally coming to rest on the ground or at a lower level." The total number of falls before and after study drug administration has been reported.

    Time frame: Up to Week 48

  7. Part 2: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 48

    Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.

    Time frame: Baseline, Week 48

  8. Part 2: Change From Baseline in the Activities of Daily Living (ADL) Score at Week 48

    The ADL scale examines the ability of participants to complete everyday tasks (e.g., holding a fork, dressing). The ADL is a 9-question assessment, with the total score being the sum of 9 questions. The ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function. Each of these is rated on a 5-point scale where 0= normal and 4= severe disability/inability to carry out activity independently, for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 48

07

Results

Posted Nov 29, 2022

Participant flow

Participants took part in the study at multiple investigative sites from 31 January 2015 to 19 December 2025.

Part 1
Participant flow — Part 1
MilestonePart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboOLE: Placebo/ OmaveloxoloneOLE: Omaveloxolone/ Omaveloxolone
Started666661210170000
Number of participants with pes cavus2232283100000
Completed666661210160000
Not completed000000010000
Withdrew: Voluntary withdrawal000000010000
Part 2
Participant flow — Part 2
MilestonePart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboOLE: Placebo/ OmaveloxoloneOLE: Omaveloxolone/ Omaveloxolone
Started00000000515200
Number of participants with pes cavus00000000101000
Completed00000000455100
Not completed000000006100
Withdrew: Administrative reasons000000002000
Withdrew: Withdrawal by subject000000004100
OLE Period
Participant flow — OLE Period
MilestonePart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboOLE: Placebo/ OmaveloxoloneOLE: Omaveloxolone/ Omaveloxolone
Started000000000010643
Part 1: randomized to placebo0000000000130
Part 1: randomized to omaveloxolone0000000000440
Part 2: randomized to placebo0000000000490
Part 2: randomized to omaveloxolone0000000000043
Completed00000000007134
Not completed0000000000359
Withdrew: Administrative reasons000000000020
Withdrew: Withdrawal by subject0000000000195
Withdrew: Reason not specified0000000000144

Outcome measures

PrimaryPart 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12

Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Watts per kilogram (W/kg)
Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 12
Watts per kilogram (W/kg)Part 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: Placebo
Part 1: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 120.14 (0.02 to 0.26)0.07 (-0.05 to 0.18)-0.09 (-0.20 to 0.03)0.06 (-0.06 to 0.18)0 (-0.11 to 0.12)0.02 (-0.06 to 0.10)0.07 (-0.02 to 0.17)0.04 (-0.03 to 0.11)
Statistical analysis
  • Part 1: Omaveloxolone 2.5 mg Followed by 5 mg vs Part 1: Placebo · Mixed models repeated measures (MMRM) · p = =0.1524 · Least square (ls) mean difference (net): 0.1 · 95% CI -0.04 to 0.23MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 10 mg vs Part 1: Placebo · MMRM · p = =0.7086 · Ls mean difference (net): 0.03 · 95% CI -0.11 to 0.16MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 20 mg vs Part 1: Placebo · MMRM · p = =0.0651 · Ls mean difference (net): -0.13 · 95% CI -0.26 to 0.01MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 40 mg vs Part 1: Placebo · MMRM · p = =0.7937 · Ls mean difference (net): 0.02 · 95% CI -0.12 to 0.15MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 80 mg vs Part 1: Placebo · MMRM · p = =0.5587 · Ls mean difference (net): -0.04 · 95% CI -0.18 to 0.10MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 160 mg vs Part 1: Placebo · MMRM · p = =0.7285 · Ls mean difference (net): -0.02 · 95% CI -0.13 to 0.09MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 300 mg vs Part 1: Placebo · MMRM · p = =0.5802 · Ls mean difference (net): 0.03 · 95% CI -0.09 to 0.15MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 2.5 mg Followed by 5 mg vs Part 1: Omaveloxolone 10 mg vs Part 1: Omaveloxolone 20 mg vs Part 1: Omaveloxolone 40 mg vs Part 1: Omaveloxolone 80 mg vs Part 1: Omaveloxolone 160 mg vs Part 1: Omaveloxolone 300 mg vs Part 1: Placebo · MMRM · p = =0.9698 · Ls mean difference (net): 0 · 95% CI -0.08 to 0.08MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
PrimaryPart 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug up to end of Part 1 of the study (up to Week 16)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: Placebo
TEAEs65566111016
TESAEs00000002
PrimaryPart 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48

The Friedreich Ataxia Rating Scale (FARS) is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48
score on a scalePart 2 Omaveloxolone 150 mgPart 2: Placebo
Part 2: Change From Baseline in the Modified Friedreich's Ataxia Rating Scale (mFARS) at Week 48-1.45 ± 4.2090.90 ± 4.305
Statistical analysis
  • Part 2 Omaveloxolone 150 mg vs Part 2: Placebo · MMRM · p = 0.0141 · Ls mean difference (net): -2.40 · 95% CI -4.31 to -0.50MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
PrimaryPart 2: Number of Participants With TEAEs and TESAEs

An AE was any unfavorable and unintended sign (including any clinically significant abnormal laboratory test result), symptom, or disease temporally associated with the use of the study drug whether or not it is considered to be study drug related. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as any AEs, regardless of relationship to study drug, that had an onset or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug up to end of Part 2 of the study (up to Week 52)
Reported as:
Count of participants · Participants
Part 2: Number of Participants With TEAEs and TESAEs
ParticipantsPart 2: Omaveloxolone 150 mgPart 2: Placebo
TEAEs5152
TESAEs53
SecondaryPart 1: Change From Baseline in the mFARS at Week 12

The FARS is a neurological-exam-based rating scale with five sections: Bulbar (section A), Upper Limb Coordination (section B), Lower Limb Coordination (section C), Peripheral Nervous System (section D), and Upright Stability (section E). mFARS is the sum of sections A (score 0 to 11), B (score 0 to 36), C (score 0 to 16), and E (score 0 to 36). The minimum score is 0 and the maximum score is 99. A lower score indicates better neurological function.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
Part 1: Change From Baseline in the mFARS at Week 12
score on a scalePart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: Placebo
Part 1: Change From Baseline in the mFARS at Week 12-3.26 (-5.82 to -0.70)-1.97 (-4.53 to 0.59)-2.44 (-5.00 to 0.12)-2.4 (-4.96 to 0.16)-2.88 (-5.44 to -0.31)-3.75 (-5.56 to -1.94)-0.88 (-2.86 to 1.11)-1.43 (-2.97 to 0.11)
Statistical analysis
  • Part 1: Omaveloxolone 2.5 mg Followed by 5 mg vs Part 1: Placebo · MMRM · p = =0.2310 · Ls mean difference (net): -1.81 · 95% CI -4.80 to 1.18MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 10 mg vs Part 1: Placebo · MMRM · p = =0.7298 · Ls mean difference (net): -0.52 · 95% CI -3.51 to 2.47MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 20 mg vs Part 1: Placebo · MMRM · p = =0.5102 · Ls mean difference (net): -0.99 · 95% CI -3.99 to 2.00MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 40 mg vs Part 1: Placebo · MMRM · p = =0.5281 · Ls mean difference (net): -0.95 · 95% CI -3.94 to 2.04MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 80 mg vs Part 1: Placebo · MMRM · p = =0.3458 · Ls mean difference (net): -1.42 · 95% CI -4.42 to 1.57MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 160 mg vs Part 1: Placebo · MMRM · p = =0.0587 · Ls mean difference (net): -2.3 · 95% CI -4.68 to 0.09MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 300 mg vs Part 1: Placebo · MMRM · p = =0.6480 · Ls mean difference (net): 0.58 · 95% CI -1.94 to 3.10MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 1: Omaveloxolone 2.5 mg Followed by 5 mg vs Part 1: Omaveloxolone 10 mg vs Part 1: Omaveloxolone 20 mg vs Part 1: Omaveloxolone 40 mg vs Part 1: Omaveloxolone 80 mg vs Part 1: Omaveloxolone 160 mg vs Part 1: Omaveloxolone 300 mg vs Part 1: Placebo · MMRM · p = =0.2174 · Ls mean difference (net): -1.1 · 95% CI -2.87 to 0.66MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
SecondaryPart 2: Number of Participants With Patient Global Impression of Change (PGI-C)

The PGI-C is a 7-point scale that requires participants to assess how much their illness has improved or worsened relative to their baseline state at the beginning of the trial. Participants self-rated their perceived change by completing the following statement: "Since I began trial treatment, my overall status is:" 1=Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse and 7=Very much worse. Lower score indicates better improvement. The categories with at least one participant having a PGI-C score are reported.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Patient Global Impression of Change (PGI-C)
ParticipantsPart 2: Omaveloxolone 150 mgPart 2: Placebo
Very Much Improved11
Much Improved32
Minimally Improved128
No Change913
Minimally Worse912
Much Worse25
SecondaryPart 2: Number of Participants With Clinical Global Impression of Change (CGI-C)

The CGIC scale is a 7 point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of an intervention. The CGIC was assessed by completing the following statement "Compared to the participant's condition at the start of the trial, this participant's overall status is", where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. Lower score indicates better improvement. The categories with at least one participant having a CGIC score are reported.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Clinical Global Impression of Change (CGI-C)
ParticipantsPart 2: Omaveloxolone 150 mgPart 2: Placebo
Much Improved22
Minimally Improved1210
No Change1517
Minimally Worse811
Much Worse01
SecondaryPart 2: Change From Baseline in Performance on a 9-Hole Peg Test (9-HPT) at Week 48

The 9-HPT is a brief, standardized, quantitative test of upper extremity (arm and hand) function. Both the dominant and nondominant hands were tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand). The participant picks up pegs 1 at a time (9 in total), using 1 hand only, and places them into holes on the board as quickly as possible, in any order until all holes are filled. Then, without pausing, the participant removes the pegs 1 at a time and returns them as quickly as possible. The times recorded for the two trials for each hand are averaged, and the reciprocal average value for each hand was used in analyses. Longer test times reflect more impairment on the participant's upper extremity function, thus a negative change from baseline suggests an improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · 1/second
Part 2: Change From Baseline in Performance on a 9-Hole Peg Test (9-HPT) at Week 48
1/secondPart 2: Omaveloxolone 150 mgPart 2: Placebo
Dominant Hand-0.0001 ± 0.00300-0.0009 ± 0.00338
Non-Dominant Hand-0.0013 ± 0.00512-0.0003 ± 0.00298
Statistical analysis
  • Part 2: Omaveloxolone 150 mg vs Part 2: Placebo · MMRM · p = =0.3659 · Ls mean difference: 0.0007 · 95% CI -0.0008 to 0.0023MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
  • Part 2: Omaveloxolone 150 mg vs Part 2: Placebo · MMRM · p = =0.1833 · Ls mean difference: -0.0013 · 95% CI -0.0032 to 0.0006MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
SecondaryPart 2: Change From Baseline in Performance on a 25-Foot Timed Walk Test (T25-FWT) at Week 48

The T25-FWT is a quantitative mobility and leg function performance test based on time (in seconds) to complete a 25-foot walk. Participants were instructed to attempt two T25-FWT trials at each visit. Both walk times were averaged, and the reciprocal average value was used in analyses. Longer test times reflect more impairment on the participant's ability to walk, thus a negative change from baseline suggests an improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · 1/second
Part 2: Change From Baseline in Performance on a 25-Foot Timed Walk Test (T25-FWT) at Week 48
1/secondPart 2: Omaveloxolone 150 mgPart 2: Placebo
Part 2: Change From Baseline in Performance on a 25-Foot Timed Walk Test (T25-FWT) at Week 48-0.0175 ± 0.02716-0.0221 ± 0.03294
Statistical analysis
  • Part 2: Omaveloxolone 150 mg vs Part 2: Placebo · MMRM · p = =0.4635 · Ls mean difference: 0.0058 · 95% CI -0.0099 to 0.0214MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
SecondaryPart 2: Total Number of Falls

A fall was defined as "the participant unintentionally coming to rest on the ground or at a lower level." The total number of falls before and after study drug administration has been reported.

Time frame:
Up to Week 48
Reported as:
Mean · number of falls
Part 2: Total Number of Falls
number of fallsPart 2: Omaveloxolone 150 mgPart 2: Placebo
Part 2: Total Number of Falls11.3 ± 20.1016.5 ± 25.69
SecondaryPart 2: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 48

Cycle ergometry using a recumbent stationary bicycle was used to conduct maximal exercise testing and workload was increased incrementally. Peak work is defined as the workload at which participants reach maximal volition (defined as an inability to continue to exercise due to exhaustion). A positive change from baseline suggests an improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · Watts/kg
Part 2: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 48
Watts/kgPart 2: Omaveloxolone 150 mgPart 2: Placebo
Part 2: Change From Baseline in Peak Work During Maximal Exercise Testing at Week 480.0397 ± 0.201060.0963 ± 0.24465
Statistical analysis
  • Part 2: Omaveloxolone 150 mg vs Part 2: Placebo · MMRM · p = =0.2155 · Ls mean difference: -0.06 · 95% CI -0.16 to 0.04MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.
SecondaryPart 2: Change From Baseline in the Activities of Daily Living (ADL) Score at Week 48

The ADL scale examines the ability of participants to complete everyday tasks (e.g., holding a fork, dressing). The ADL is a 9-question assessment, with the total score being the sum of 9 questions. The ADL survey assesses 9 concepts: (1) speech; (2) swallowing; (3) cutting food and handling utensils; (4) dressing; (5) personal hygiene; (6) falling; (7) walking; (8) quality of sitting position; and (9) bladder function. Each of these is rated on a 5-point scale where 0= normal and 4= severe disability/inability to carry out activity independently, for a total possible score of 0 to 36, with higher scores representing greater disability/dependency. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · score on a scale
Part 2: Change From Baseline in the Activities of Daily Living (ADL) Score at Week 48
score on a scalePart 2: Omaveloxolone 150 mgPart 2: Placebo
Part 2: Change From Baseline in the Activities of Daily Living (ADL) Score at Week 48-0.222 ± 3.03651.183 ± 2.5440
Statistical analysis
  • Part 2: Omaveloxolone 150 mg vs Part 2: Placebo · MMRM · p = =0.0420 · Ls mean difference: -1.3 · 95% CI -2.56 to -0.05MMRM with treatment group, time, and the interaction between treatment and time were used as fixed factors.

Adverse events

Collected over From first dose of study drug up to end of OLE period (up to approximately 130 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Omaveloxolone 2.5 mg Followed by 5 mg0/6 (0%)0/6 (0%)6/6 (100%)
Part 1: Omaveloxolone 10 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part 1: Omaveloxolone 20 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Part 1: Omaveloxolone 40 mg0/6 (0%)0/6 (0%)6/6 (100%)
Part 1: Omaveloxolone 80 mg0/6 (0%)0/6 (0%)6/6 (100%)
Part 1: Omaveloxolone 160 mg0/12 (0%)0/12 (0%)11/12 (91.7%)
Part 1: Omaveloxolone 300 mg0/10 (0%)0/10 (0%)10/10 (100%)
Part 1: Placebo0/17 (0%)2/17 (11.8%)16/17 (94.1%)
Part 2: Omaveloxolone 150 mg0/51 (0%)5/51 (9.8%)51/51 (100%)
Part 2: Placebo0/52 (0%)3/52 (5.8%)50/52 (96.2%)
OLE: Placebo/ Omaveloxolone0/106 (0%)12/106 (11.3%)103/106 (97.2%)
OLE: Omaveloxolone/ Omaveloxolone0/43 (0%)13/43 (30.2%)42/43 (97.7%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboOLE: Placebo/ OmaveloxoloneOLE: Omaveloxolone/ Omaveloxolone
Drug withdrawal syndromeGeneral disorders0/60/60/60/60/60/120/101/170/510/520/1060/43
Burns third degreeInjury, poisoning and procedural complications0/60/60/60/60/60/120/101/170/510/520/1060/43
Left ventricular failureCardiac disorders0/60/60/60/60/60/120/100/170/510/520/1061/43
Sinus tachycardiaCardiac disorders0/60/60/60/60/60/120/100/171/510/520/1061/43
ConstipationGastrointestinal disorders0/60/60/60/60/60/120/100/170/510/520/1061/43
DiarrhoeaGastrointestinal disorders0/60/60/60/60/60/120/100/170/510/520/1061/43
PainGeneral disorders0/60/60/60/60/60/120/100/170/510/520/1061/43
GastroenteritisInfections and infestations0/60/60/60/60/60/120/100/170/510/520/1061/43
Lower respiratory tract infectionInfections and infestations0/60/60/60/60/60/120/100/170/510/520/1061/43
Pilonidal diseaseInfections and infestations0/60/60/60/60/60/120/100/170/510/520/1061/43
Most frequent other events
Showing 10 of 129
Most frequent other events
EventPart 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboOLE: Placebo/ OmaveloxoloneOLE: Omaveloxolone/ Omaveloxolone
Upper respiratory tract infectionInfections and infestations2/61/65/62/62/64/126/101/1714/5115/5224/10613/43
Covid-19Infections and infestations0/60/60/60/60/60/120/100/170/510/5249/10624/43
FatigueGeneral disorders3/60/60/60/62/61/120/102/1711/517/5213/1067/43
Alanine aminotransferase increasedInvestigations1/60/60/61/60/62/122/100/1719/511/5225/1064/43
HeadacheNervous system disorders1/60/60/60/62/64/122/103/1719/5113/5221/1068/43
ContusionInjury, poisoning and procedural complications0/60/60/60/60/61/121/100/1717/5119/5220/1068/43
NauseaGastrointestinal disorders0/61/60/60/61/61/122/101/1717/517/5222/1067/43
Influenza like illnessGeneral disorders0/60/60/62/60/60/120/101/173/511/520/1060/43
NasopharyngitisInfections and infestations0/60/60/61/61/63/123/100/177/519/526/1069/43
ArthralgiaMusculoskeletal and connective tissue disorders1/61/60/60/60/61/122/100/179/5110/5228/1069/43

Baseline characteristics

Part 1: The Intent-to-treat (ITT) population included all enrolled participants in Part 1, whether or not they received the study drug. Part 2: All Randomized Population (ARP) included all participants randomized, categorized by their randomized treatment group (whether or not they received study drug).

Age, Continuous
Age, Continuous(years)Part 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboTotal
Mean25.8 ± 5.9825.5 ± 7.428.3 ± 6.827.7 ± 7.5324.3 ± 4.825.3 ± 6.5125.6 ± 7.2424.4 ± 6.7423.4 ± 6.0824.1 ± 7.8524.5 ± 6.84
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboTotal
Female445135510311785
Male22153757203587
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboTotal
Hispanic or Latino01000001237
Not Hispanic or Latino656661210164949165
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Omaveloxolone 2.5 mg Followed by 5 mgPart 1: Omaveloxolone 10 mgPart 1: Omaveloxolone 20 mgPart 1: Omaveloxolone 40 mgPart 1: Omaveloxolone 80 mgPart 1: Omaveloxolone 160 mgPart 1: Omaveloxolone 300 mgPart 1: PlaceboPart 2: Omaveloxolone 150 mgPart 2: PlaceboTotal
American Indian or Alaska Native00000000000
Asian00000000000
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00000000000
White666661110165050167
More than one race00000000000
Unknown or Not Reported00000101125
08

Study locations

11 sites
  • UCLA
    Los Angeles, California 90095, United States
  • University of Florida - Neurology
    Gainesville, Florida 32610, United States
  • USF Ataxia Research Center
    Tampa, Florida 33612, United States
  • Emory University Hospital - Neurology
    Atlanta, Georgia 30329, United States
  • University of Iowa Stead Family Children's Hospital
    Iowa City, Iowa 52242, United States
  • Ohio State University - Neurology
    Columbus, Ohio 43221, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Murdoch Childrens Research Institute
    Parkville, Victoria 3052, Australia
  • Medical University Innsbruck
    Innsbruck, 6020, Austria
  • Neurological Institute Carlo Besta
    Milan, 20133, Italy
  • University College of London
    London, WC1E 6BT, United Kingdom
09

References and documents

Publications

  • Perlman S, Zhang S, Setyawan J, Yang H, Jiang A, Hua Q, Boudreau J, Khan S, Bajaj A, Lynch DR, Lawson R. The clinical burden of Friedreich ataxia in the United States: A retrospective claims database analysis. J Neurol Sci. 2025 Aug 15;475:123594. doi: 10.1016/j.jns.2025.123594. Epub 2025 Jun 25. PubMed 40614535 ↗
  • Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, Giunti P, Wilmot G, Zesiewicz T, Perlman S, Goldsberry A, O'Grady M, Meyer CJ. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021 Feb;89(2):212-225. doi: 10.1002/ana.25934. Epub 2020 Nov 5. PubMed 33068037 ↗
  • Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan. PubMed 30656180 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Oct 2019, 57 months.

Results were first posted in Nov 2022, 3 years after primary completion. A results delay was requested in Oct 2020.

Of 12 phase 2 interventional studies under Friedreich Ataxia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 34. This study's 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2014
First posted
Oct 2, 2014
StartActual
Jan 31, 2015
Primary completionActual
Oct 31, 2019
CompletionActual
Dec 19, 2025
Results delay requested
Oct 1, 2020
Results first posted
Nov 29, 2022
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02255435
Lead sponsor
Biogen
Collaborators
AbbVie, Friedreich's Ataxia Research Alliance
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
Jan 31, 2015
Primary completion
Oct 31, 2019
Completion
Dec 19, 2025
Results posted
Nov 29, 2022
Last update
Sep 3, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion